Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Enterprise Value (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Enterprise Value readings, the most recent being -$51.4 million for Q4 2025.

  • Quarterly Enterprise Value rose 12.62% to -$51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$51.4 million through Dec 2025, up 12.62% year-over-year, with the annual reading at -$51.4 million for FY2025, 12.62% up from the prior year.
  • Enterprise Value hit -$51.4 million in Q4 2025 for Oramed Pharmaceuticals, up from -$58.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$24.2 million in Q2 2025 and bottomed at -$155.0 million in Q3 2022.
  • Average Enterprise Value over 5 years is -$77.0 million, with a median of -$65.8 million recorded in 2021.
  • The largest annual shift saw Enterprise Value crashed 413.7% in 2021 before it soared 72.27% in 2025.
  • Oramed Pharmaceuticals' Enterprise Value stood at -$38.9 million in 2021, then fell by 15.28% to -$44.9 million in 2022, then tumbled by 50.89% to -$67.7 million in 2023, then increased by 13.17% to -$58.8 million in 2024, then grew by 12.62% to -$51.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Enterprise Value are -$51.4 million (Q4 2025), -$58.1 million (Q3 2025), and -$24.2 million (Q2 2025).